Edivoxetine
Edivoxetine[edit | edit source]
Edivoxetine is a pharmaceutical compound that was under development as a potential treatment for major depressive disorder (MDD). It is classified as a selective norepinephrine reuptake inhibitor (NRI), which means it primarily affects the neurotransmitter norepinephrine in the brain. Edivoxetine was being developed by the pharmaceutical company Eli Lilly and Company.
Pharmacology[edit | edit source]
Edivoxetine functions by inhibiting the reuptake of norepinephrine, thereby increasing its availability in the synaptic cleft. This mechanism is thought to contribute to its potential antidepressant effects. Unlike some other antidepressants, edivoxetine does not significantly affect the reuptake of serotonin or dopamine, making it a more selective agent.
Development and Clinical Trials[edit | edit source]
Edivoxetine was evaluated in several clinical trials to assess its efficacy and safety in treating major depressive disorder. However, the results from these trials were not sufficiently positive to support its continued development for this indication. The trials indicated that while edivoxetine was generally well-tolerated, its efficacy in alleviating symptoms of depression was not significantly better than placebo.
Potential Uses[edit | edit source]
Although its development for major depressive disorder was discontinued, edivoxetine's pharmacological profile suggests it could be explored for other conditions where norepinephrine modulation might be beneficial. These could include attention deficit hyperactivity disorder (ADHD) or certain types of anxiety disorders. However, as of the latest updates, no further development has been reported.
Chemical Properties[edit | edit source]
Edivoxetine is a small molecule with a specific chemical structure that allows it to selectively inhibit norepinephrine reuptake. The chemical structure of edivoxetine is depicted in the accompanying images, which illustrate both the structural formula and a ball-and-stick model.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
